Artificial Intelligence in Diabetes Management Market
完整報告名稱與涵蓋範圍
Artificial Intelligence in Diabetes Management Market Research Report by Type (Diagnostics, Treatment Planning, Data Management, Patient Self-Management), by Deployment (Cloud-Based, On-Premises, Hybrid), by Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), by end-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diabetes Treatment Centers, Patients), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035
報告摘要
Valued at USD 1,568.64 million in 2024, the Global Artificial Intelligence in Diabetes Management Market is anticipated to expand significantly, reaching USD 14,239.56 million by 2035. This growth reflects a strong CAGR of 22.76% over the 2025–2035 period, fueled by advancements in AI-based diagnostics and monitoring tools.
Expansion of Connected Diabetes Devices
The rapid adoption of connected devices such as CGMs, smart insulin pens, and AI-enabled wearables is a primary driver of the Global Artificial Intelligence in Diabetes Management Market, enabling real-time monitoring and personalized treatment. These technologies significantly improve glycemic control, treatment adherence, and proactive prevention of complications.
Concise Segment Insights
By Type
• Diagnostics: AI enables faster, accurate diabetes detection
• Treatment Planning: Personalized AI-driven insulin and therapy optimization
• Data Management: Efficient handling of large patient datasets
• Patient Self-Management: AI tools support daily glucose monitoring
By Deployment
• Cloud-Based: Scalable platforms enable real-time data access
• On-Premises: Ensures data security and local system control
• Hybrid: Combines flexibility with enhanced data protection
By Application
• Type 1 Diabetes: Continuous monitoring and insulin dose precision
• Type 2 Diabetes: Lifestyle tracking with AI-based intervention insights
• Gestational Diabetes: Temporary monitoring ensuring maternal-fetal health
By End-User
• Hospitals and Clinics: Advanced AI tools improve clinical decision-making
• Ambulatory Surgical Centers: Efficient monitoring during outpatient procedures
• Diabetes Treatment Centers: Specialized care with AI-driven analytics
• Patients: Self-care tools enhance engagement and adherence
Regional Market Snapshot
North America dominates with over 40% share driven by advanced infrastructure, while Europe follows with strong regulatory-backed adoption and healthcare integration. Asia Pacific shows the fastest expansion due to high prevalence and digital growth, while South America and MEA emerge steadily with cost-effective, mobile-first AI solutions.
Strategic AI Collaboration Initiative
In May 2024, Sanofi partnered with Formation Bio and OpenAI to develop AI-powered solutions aimed at accelerating drug discovery and development. This collaboration integrates proprietary data, advanced software, and tailored AI models to enhance efficiency across the pharmaceutical lifecycle.
AI-Driven Personalization Advantage
The integration of generative AI and predictive analytics provides a strategic edge by enabling highly personalized diabetes management through synthetic data generation and advanced modeling. These technologies enhance clinical decision-making, improve treatment precision, and support proactive intervention strategies.
Key Report Attributes
• Market Size 2024: USD 1568.64 Million
• Market Size 2035: USD 14239.56 Million
• CAGR (2025-2035): 22.76%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Industry Segmentations Growth
• By Type: Diagnostics - 23.03%, Treatment Planning - 22.27%.
• By Deployment: Cloud-Based - 23.68%, On-Premises - 22.21%.
• By Application: Type 1 Diabetes - 25.39%, Type 2 Diabetes - 22.43%.
• By end-User: Hospitals and Clinics - 22.05%, Ambulatory Surgical Centers - 22.34%.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ...... 20
2 MARKET INTRODUCTION ...... 22
2.1 DEFINITION ...... 22
2.2 SCOPE OF THE STUDY ....... 22
2.3 RESEARCH OBJECTIVE ........ 22
2.4 MARKET STRUCTURE ....... 23
3 RESEARCH METHODOLOGY ...... 24
3.1 OVERVIEW ........ 24
3.2 DATA FLOW ...... 26
3.2.1 DATA MINING PROCESS ...... 26
3.3 PURCHASED DATABASE: ........ 27
3.4 SECONDARY SOURCES: ........ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: ....... 29
3.5 PRIMARY RESEARCH: ........ 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ....... 32
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ........ 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ....... 33
3.6.1 REVENUE ANALYSIS APPROACH ...... 33
3.7 DATA FORECASTING....... 34
3.7.1 DATA FORECASTING TYPE ...... 34
3.8 DATA MODELING ........ 35
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ...... 35
3.8.2 DATA MODELING: ....... 36
3.9 TEAMS AND ANALYST CONTRIBUTION ........ 38
4 MARKET DYNAMICS ........ 40
4.1 INTRODUCTION ........ 40
4.2 DRIVERS ....... 41
4.2.1 RISING GLOBAL DIABETES PREVALENCE ...... 41
4.2.2 ADVANCEMENTS IN CONNECTED DEVICES AND DIGITAL HEALTH INFRASTRUCTURE ...... 42
4.2.3 SHIFT TOWARD PERSONALIZED AND PREDICTIVE HEALTHCARE....... 42
4.2.4 INCREASED ADOPTION OF CLOUD AND SAAS HEALTHCARE PLATFORMS ........ 42
4.3 RESTRAINTS ....... 44
4.3.1 HIGH IMPLEMENTATION AND INTEGRATION COSTS ....... 44
4.3.2 DATA PRIVACY AND CYBERSECURITY CONCERNS ....... 44
4.3.3 LIMITED INTEROPERABILITY ACROSS DEVICES AND EHR SYSTEMS ........ 44
4.4 OPPORTUNITIES ...... 45
4.4.1 EXPANSION OF REMOTE PATIENT MONITORING (RPM) AND TELEHEALTH ....... 45
4.4.2 EMERGENCE OF GENERATIVE AI AND PREDICTIVE ANALYTICS ...... 46
4.4.3 PARTNERSHIPS BETWEEN TECH GIANTS AND HEALTHCARE PROVIDERS ...... 47
5 MARKET FACTOR ANALYSIS ...... 48
5.1 VALUE CHAIN ANALYSIS ...... 48
5.1.1 DATA GENERATION & ACQUISITION ....... 48
5.1.2 DATA PROCESSING & STORAGE ....... 48
5.1.3 AI MODEL DEVELOPMENT ...... 48
5.1.4 INTEGRATION WITH DEVICES & PLATFORMS ...... 49
5.1.5 CLINICAL VALIDATION & REGULATORY APPROVAL ...... 49
5.1.6 DEPLOYMENT & COMMERCIALIZATION ........ 49
5.1.7 PATIENT ENGAGEMENT & FEEDBACK ....... 49
5.1.8 CONTINUOUS LEARNING & MODEL OPTIMIZATION ...... 49
5.2 PORTER'S FIVE FORCES MODEL ...... 50
5.2.1 THREAT OF NEW ENTRANTS ...... 51
5.2.2 BARGAINING POWER OF SUPPLIERS ...... 51
5.2.3 THREAT OF SUBSTITUTES ...... 51
5.2.4 BARGAINING POWER OF BUYERS ........ 51
5.2.5 INTENSITY OF RIVALRY ....... 51
5.3 COVID-19 IMPACT ANALYSIS ........ 51
6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE ........ 54
6.1 OVERVIEW ........ 54
6.1.1 DIAGNOSTICS ...... 56
6.1.2 TREATMENT PLANNING ...... 57
6.1.3 DATA MANAGEMENT ....... 57
6.1.4 PATIENT SELF MANAGEMENT ...... 58
7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT….. 59
7.1 OVERVIEW ........ 59
7.1.1 CLOUD-BASED ...... 61
7.1.2 ON-PREMISES ...... 61
7.1.3 HYBRID ....... 62
8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION ….. 63
8.1 OVERVIEW ........ 63
8.1.1 TYPE 1 DIABETES ....... 65
8.1.2 TYPE 2 DIABETES ....... 65
8.1.3 GESTATIONAL DIABETES ........ 66
9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER ….. 67
9.1 OVERVIEW ........ 67
9.1.1 HOSPITALS AND CLINICS ....... 69
9.1.2 AMBULATORY SURGICAL CENTERS ........ 70
9.1.3 DIABETES TREATMENT CENTERS........ 70
9.1.4 PATIENTS ...... 71
10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION ... 72
10.1 OVERVIEW ........ 72
10.2 NORTH AMERICA ....... 73
10.2.1 US...... 76
10.2.2 CANADA ........ 78
10.3 EUROPE ........ 81
10.3.1 GERMANY ...... 84
10.3.2 FRANCE ...... 86
10.3.3 UK ........ 88
10.3.4 SPAIN ...... 90
10.3.5 ITALY ....... 92
10.3.6 RUSSIA ....... 94
10.3.7 REST OF EUROPE ........ 96
10.4 ASIA-PACIFIC ...... 98
10.4.1 CHINA ...... 101
10.4.2 INDIA ....... 103
10.4.3 JAPAN ........ 105
10.4.4 SOUTH KOREA ...... 107
10.4.5 MALAYSIA ........ 109
10.4.6 THAILAND ...... 110
10.4.7 INDONESIA ........ 112
10.4.8 REST OF ASIA-PACIFIC ........ 114
10.5 SOUTH AMERICA ....... 116
10.5.1 BRAZIL ........ 119
10.5.2 MEXICO ...... 121
10.5.3 ARGENTINA ...... 123
10.5.4 REST OF SOUTH AMERICA ...... 125
10.6 MIDDLE EAST & AFRICA ...... 127
10.6.1 GCC COUNTRIES...... 131
10.6.2 SOUTH AFRICA ........ 133
10.6.3 REST OF MEA ....... 135
11 COMPETITIVE LANDSCAPE ........ 138
11.1 INTRODUCTION ........ 138
11.2 MARKET SHARE ANALYSIS, 2024 ........ 138
11.3 COMPETITOR DASHBOARD....... 139
11.4 PUBLIC PLAYERS STOCK SUMMARY ........ 140
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ...... 140
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ........ 141
11.1.1 PRODUCT LAUNCH ........ 141
11.1.2 PARTNERSHIP ...... 141
11.1.3 ACQUISITION/ EXPANSION ........ 141
11.1.4 AI-ENABLED ...... 142
12 COMPANY PROFILES ...... 143
12.1 ELI LILLY AND COMPANY ...... 143
12.1.1 COMPANY OVERVIEW ....... 143
12.1.2 FINANCIAL OVERVIEW ...... 145
12.1.3 PRODUCTS/ SERVICE OFFERED ........ 146
12.1.4 KEY DEVELOPMENTS ........ 146
12.1.5 SWOT ANALYSIS ........ 147
12.1.6 KEY STRATEGIES ........ 147
12.2 ASTRAZENECA...... 148
12.2.1 COMPANY OVERVIEW ....... 148
12.2.2 FINANCIAL OVERVIEW ...... 149
12.2.3 PRODUCTS OFFERED ........ 150
12.2.4 KEY DEVELOPMENTS ........ 150
12.2.5 SWOT ANALYSIS ........ 151
12.2.6 KEY STRATEGIES ........ 151
12.3 SANOFI ...... 152
12.3.1 COMPANY OVERVIEW ....... 152
12.3.2 FINANCIAL OVERVIEW ...... 153
12.3.3 PRODUCTS OFFERED ........ 154
12.3.4 KEY DEVELOPMENTS ........ 154
12.3.5 KEY STRATEGIES ........ 154
12.4 NOVO NORDISK A/S ...... 156
12.4.1 COMPANY OVERVIEW ....... 156
12.4.2 FINANCIAL OVERVIEW ...... 157
12.4.3 PRODUCTS OFFERED ........ 158
12.4.4 KEY DEVELOPMENTS ........ 158
12.4.5 SWOT ANALYSIS ........ 159
12.4.6 KEY STRATEGIES ........ 159
12.5 TANDEM DIABETES CARE, INC. ....... 160
12.5.1 COMPANY OVERVIEW ....... 160
12.5.2 FINANCIAL OVERVIEW ...... 161
12.5.3 PRODUCTS OFFERED ........ 162
12.5.4 KEY DEVELOPMENTS ........ 162
12.5.5 SWOT ANALYSIS ........ 163
12.5.6 KEY STRATEGIES ........ 163
12.6 F. HOFFMANN-LA ROCHE LTD. ........ 164
12.6.1 COMPANY OVERVIEW ....... 164
12.6.2 FINANCIAL OVERVIEW ...... 165
12.6.3 PRODUCTS/SERVICES OFFERED ....... 166
12.6.4 KEY DEVELOPMENTS ........ 166
12.6.5 SWOT ANALYSIS ........ 167
12.6.6 KEY STRATEGIES ........ 167
12.7 ABBOTT ........ 168
12.7.1 COMPANY OVERVIEW ....... 168
12.7.2 FINANCIAL OVERVIEW ...... 169
12.7.3 PRODUCTS/SERVICES OFFERED ....... 169
12.7.4 KEY DEVELOPMENTS ........ 170
12.7.5 KEY STRATEGIES ........ 170
12.8 MEDTRONIC ........ 171
12.8.1 COMPANY OVERVIEW ....... 171
12.8.2 FINANCIAL OVERVIEW ...... 172
12.8.3 PRODUCTS/SERVICES OFFERED ....... 173
12.8.4 KEY DEVELOPMENTS ........ 173
12.8.5 SWOT ANALYSIS ........ 173
12.8.6 KEY STRATEGIES ........ 174
12.9 DEXCOM INC. ...... 175
12.9.1 COMPANY OVERVIEW ....... 175
12.9.2 FINANCIAL OVERVIEW ...... 176
12.9.3 PRODUCTS/SERVICES OFFERED ....... 177
12.9.4 KEY DEVELOPMENTS ........ 177
12.9.5 KEY STRATEGIES ........ 177
12.10 INSULET CORPORATION ...... 178
12.10.1 COMPANY OVERVIEW ....... 178
12.10.2 FINANCIAL OVERVIEW ...... 179
12.10.3 PRODUCTS/SERVICES OFFERED ....... 179
12.10.4 KEY DEVELOPMENTS ........ 180
12.10.5 SWOT ANALYSIS ........ 180
12.10.6 KEY STRATEGY ........ 181
13 DATA CITATIONS ....... 182
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37
TABLE 2 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 55
TABLE 3 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DIAGNOSTICS, BY REGION, 2019–2035 (USD MILLION) 56
TABLE 4 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TREATMENT PLANNING, BY REGION, 2019–2035 (USD MILLION) 57
TABLE 5 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DATA MANAGEMENT, BY REGION, 2019–2035 (USD MILLION) 57
TABLE 6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR PATIENT SELF MANAGEMENT, BY REGION, 2019
2035 (USD MILLION) 58
TABLE 7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 60
TABLE 8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR CLOUD-BASED, BY REGION, 2019–2035 (USD MILLION) 61
TABLE 9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR ON-PREMISES, BY REGION, 2019–2035 (USD MILLION) 61
TABLE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR HYBRID, BY REGION, 2019–2035 (USD MILLION) 62
TABLE 11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 64
TABLE 12 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TYPE 1 DIABETES, BY REGION, 2019–2035 (USD MILLION) 65
TABLE 13 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TYPE 2 DIABETES, BY REGION, 2019–2035 (USD MILLION) 65
TABLE 14 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR GESTATIONAL DIABETES, BY REGION, 2019–2035 (USD MILLION) 66
TABLE 15 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 68
TABLE 16 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2019–2035 (USD MILLION) 69
TABLE 17 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019–2035 (USD MILLION) 70
TABLE 18 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DIABETES TREATMENT CENTERS, BY REGION, 2019-2035 (USD MILLION) 70
TABLE 19 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR PATIENTS, BY REGION, 2019–2035 (USD MILLION)
TABLE 20 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION, 2019-2035 (USD MILLION) 72
TABLE 21 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 74
TABLE 22 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 75
TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION)
TABLE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 25 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 76
TABLE 26 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 76
TABLE 27 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 77
TABLE 28 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77
TABLE 29 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 78
TABLE 30 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 78
TABLE 31 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 79
TABLE 32 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 79
TABLE 33 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 80
TABLE 34 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 82
TABLE 35 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 83
TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 83
TABLE 37 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83
TABLE 38 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 84
TABLE 39 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 84
TABLE 40 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 85
TABLE 41 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 85
TABLE 42 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 85
TABLE 43 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 86
TABLE 44 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 86
TABLE 45 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 87
TABLE 46 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 87
TABLE 47 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 88
TABLE 48 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 88
TABLE 49 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 89
TABLE 50 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 89
TABLE 51 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 90
TABLE 52 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 90
TABLE 53 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 91
TABLE 54 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 91
TABLE 55 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 92
TABLE 56 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 92
TABLE 57 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 93
TABLE 58 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 93
TABLE 59 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 94
TABLE 60 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 94
TABLE 61 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95
TABLE 62 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 95
TABLE 63 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 96
TABLE 64 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION)
TABLE 65 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 66 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 97
TABLE 67 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 99
TABLE 68 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 100
TABLE 69 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 100
TABLE 70 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 100
TABLE 71 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 101
TABLE 72 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 101
TABLE 73 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 102
TABLE 74 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102
TABLE 75 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 102
TABLE 76 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 103
TABLE 77 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 103
TABLE 78 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104
TABLE 79 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 104
TABLE 80 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 105
TABLE 81 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 105
TABLE 82 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106
TABLE 83 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 106
TABLE 84 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 107
TABLE 85 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 107
TABLE 86 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 108
TABLE 87 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 108
TABLE 88 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 109
TABLE 89 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 109
TABLE 90 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109
TABLE 91 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 110
TABLE 92 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 110
TABLE 93 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 111
TABLE 94 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111
TABLE 95 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 111
TABLE 96 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 112
TABLE 97 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 112
TABLE 98 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113
TABLE 99 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 113
TABLE 100 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 114
TABLE 101 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 114
TABLE 102 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115
TABLE 103 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION)
TABLE 104 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 117
TABLE 105 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) 118
TABLE 106 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION)
TABLE 107 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 108 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 119
TABLE 109 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 110 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 120
TABLE 111 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 120
TABLE 112 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 120
TABLE 113 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) 121
TABLE 114 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 121
TABLE 115 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 116 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 117 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 118 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION)
TABLE 119 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 120 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 121 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 122 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION)
TABLE 123 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 124 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 125 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)128
TABLE 126 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION)
TABLE 128 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 129 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 130 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 131 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION)
TABLE 132 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)132
TABLE 133 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 132
TABLE 134 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 135 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 133
TABLE 136 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 134
TABLE 137 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 138 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION)
TABLE 139 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 135
TABLE 140 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 136
TABLE 141 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION)
TABLE 142 PRODUCT LAUNCH
TABLE 143 PARTNERSHIP
TABLE 144 ACQUISITION/ EXPANSION
TABLE 145 AI-ENABLED
TABLE 146 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 147 ASTRAZENECA: PRODUCTS OFFERED
TABLE 148 SANOFI: PRODUCTS OFFERED
TABLE 149 SANOFI: KEY DEVELOPMENTS
TABLE 150 NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 151 TANDEM DIABETES CARE, INC.: PRODUCTS OFFERED
TABLE 152 TANDEM DIABETES CARE, INC.: KEY DEVELOPMENTS
TABLE 153 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 154 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 155 ABBOTT.: PRODUCTS/SERVICES OFFERED
TABLE 156 MEDTRONIC: PRODUCTS/SERVICES OFFERED
TABLE 157 MEDTRONIC: KEY DEVELOPMENTS
TABLE 158 DEXCOM, INC: PRODUCTS/SERVICES OFFERED
TABLE 159 INSULET CORPORATION.: PRODUCTS/SERVICES OFFERED
TABLE 160 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DIABETES MANAGEMENT MARKET: STRUCTURE 23
FIGURE 1 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 40
FIGURE 2 SHARE OF PEOPLE WITH DIABETES, 2024 41
FIGURE 3 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET DRIVER: IMPACT ANALYSIS 43
FIGURE 4 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET RESTRAINT: IMPACT ANALYSIS 45
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DIABETES MANAGEMENT MARKET 50
FIGURE 6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 54
FIGURE 7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2024 & 2035 (USD MILLION) 55
FIGURE 8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY TYPE, 2024 56
FIGURE 9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, DEPLOYMENT SEGMENT ATTRACTIVENESS, 2024 & 2035
(USD MILLION) 59
FIGURE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2024 & 2035 (USD MILLION) 59
FIGURE 11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY DEPLOYMENT, 2024 60
FIGURE 12 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 63
FIGURE 13 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 63
FIGURE 14 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY APPLICATION, 2024 64
FIGURE 15 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 67
FIGURE 16 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2024 & 2035 (USD MILLION) 68
FIGURE 17 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY END USER, 2024 69
FIGURE 18 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION, 2024 & 2035 (USD MILLION) 72
FIGURE 19 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY REGION, 2024 73
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION)
FIGURE 21 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 74
FIGURE 22 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 74
FIGURE 23 EUROPE MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION) 81
FIGURE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 81
FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 82
FIGURE 1 ASIA-PACIFIC MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION) 98
FIGURE 2 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
FIGURE 3 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY COUNTRY, 2024 (%) 99
FIGURE 4 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: SWOT ANALYSIS 116
FIGURE 5 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET (, BY COUNTRY, 2024 & 2035 (USD MILLION) 116
FIGURE 6 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 117
FIGURE 7 MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: SWOT ANALYSIS 127
FIGURE 8 MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET (, BY COUNTRY, 2024 & 2035 (USD MILLION) 127
FIGURE 9 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 128
FIGURE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 11 COMPETITOR DASHBOARD: GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET
FIGURE 12 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 14 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ASTRAZENECA: SWOT ANALYSIS
FIGURE 16 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 NOVO NORDISK A/S: SWOT ANALYSIS
FIGURE 19 TANDEM DIABETES CARE, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 TANDEM DIABETES CARE, INC.: SWOT ANALYSIS
FIGURE 21 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
FIGURE 23 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 MEDTRONIC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 MEDTRONIC: SWOT ANALYSIS
FIGURE 26 DEXCOM, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 INSULET CORPORATION.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 INSULET CORPORATION.: SWOT ANALYSIS
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們